FDA Approval Sought for Tazemetostat in Follicular Lymphoma

A new drug application has been submitted to the FDA for tazemetostat as a treatment for patients with relapsed/refractory follicular lymphoma, with or without EZH2 activating mutations, who have received ≥2 prior lines of systemic therapy.

Read the full article here

Related Articles